$71.92
Value $3.8B
CBT and ECL stock compared: price, dividend, valuation and results, from SEC filings.
$71.92
Value $3.8B
$309.27
Value $87.2B
Cabot (CBT) has a market value of $3.8B and Ecolab (ECL) $87.2B. Over the last year, with dividends, CBT moved +19.8% and ECL +19.8%. The P/E is 20.3 for CBT and 41.9 for ECL. Dividend yield: CBT 2.57%, ECL 0.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CBT$3.8B
ECL$87.2B
ECL is 23 times CBT
Revenue, 12 months
CBT$3.6B
ECL$17.4B
ECL is 4.8 times CBT
Net income, 12 months
CBT$190M
ECL$2.1B
ECL is 11 times CBT
Operating margin
CBT13.6%
ECL16.7%
3.1 points apart
ROIC
CBT14.4%
ECL11.6%
2.8 points apart
P/E
CBT20.3
ECL41.9
ECL is 2.1 times CBT
Dividend yield
CBT2.6%
ECL0.9%
1.7 points apart
5-year return
CBT+37.1%
ECL+38.8%
1.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CBT+37.1%
ECL+38.8%
| Period | CBTWith dividends | ECLWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +19.8%Price +17.0% | +19.8%Price +18.5% |
| 3 years since November 13, 2023 | +3.4%+1.1% a yearPrice -2.9% | +78.2%+21.2% a yearPrice +72.8% |
| 5 years since November 12, 2021 | +37.1%+6.5% a yearPrice +23.4% | +38.8%+6.8% a yearPrice +31.2% |
| 10 years since November 14, 2016 | +77.4%+5.9% a yearPrice +39.2% | +202.4%+11.7% a yearPrice +171.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CBTCabotECLEcolab
| Price | $71.92 | $309.27 |
|---|---|---|
| Market value | $3.8B | $87.2B |
| Enterprise value (EV) | $4.8B | $99.7B |
| P/E | 20.3 | 41.9 |
| P/E, 5-year median | 12.6 | 38.2 |
| P/B | 2.4 | 8.4 |
| EV/EBIT | 9.8 | 34.3 |
| Free cash flow yield | 7.4% | 2.1% |
| Revenue, 12 months | $3.6B | $17.4B |
|---|---|---|
| Net income, 12 months | $190M | $2.1B |
| Free cash flow, 12 months | $281M | $1.8B |
| Earnings per share, 12 months | $3.56 | $7.35 |
| Revenue growth, year on year | -7.0% | 2.2% |
| Revenue growth a year, past | +7.3%over 5 years | +6.4%over 5 years |
| EPS growth a year, past | – | – |
| Gross margin | 22.7% | 43.9% |
|---|---|---|
| Operating margin | 13.6% | 16.7% |
| Net margin | 5.2% | 12.0% |
| ROIC | 14.4% | 11.6% |
| ROE | 12.1% | 20.8% |
| Cash | $250M | $722M |
|---|---|---|
| Total debt | $1.3B | $13.4B |
| Net debt / EBITDA | 1.6 | 3.5 |
| Interest cover | 6.7× | 7.4× |
| Dividend yield | 2.6% | 0.9% |
|---|---|---|
| Dividend per share, 12 months | $1.85 | $2.92 |
| Dividend growth a year, past | +4.7%over 5 years | +7.2%over 5 years |
| Buyback yield | 4.4% | 0.9% |
| Shareholder yield | 7.0% | 1.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Ecolab ($87.2B) is about 22.9 times Cabot ($3.8B), at today's prices.
Since November 14, 2016, CBT's price moved +39.2% and ECL's +171.3%. With dividends: CBT +77.4% (+5.9% a year), ECL +202.4% (+11.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.57% for Cabot and 0.94% for Ecolab. Over the last twelve months they paid $1.85 and $2.92 per share.
At today's price, the P/E is 20.3 for CBT and 41.9 for ECL. The median of the last five years was 12.6 and 38.2, which shows where each stands against its own past.
Over the last twelve months, the net margin was 5.2% for Cabot and 12.0% for Ecolab, and the operating margin 13.6% and 16.7%. Revenue was $3.6B and $17.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.